Gücer F, Moser F, Tamussino K, Reich O, Haas J, Arikan G, Petru E, Winter R
Department of Obstetrics and Gynecology, University of Graz, Graz, A-8036, Austria.
Gynecol Oncol. 1998 Aug;70(2):210-4. doi: 10.1006/gyno.1998.5078.
We reviewed the prevalence of thrombocytosis (platelet count >/=400, 000/microL) and its association with outcome in 135 consecutive endometrial carcinoma patients and compared the platelet count with other prognostic factors. Nineteen of 135 patients (14%) had thrombocytosis. Thrombocytosis was significantly more frequent in advanced disease (stage II-IV), unfavorable grade (G2 and G3), deep myometrial invasion, and lymph-vascular space invasion. The overall 5-year survival rate was 92%. The 5-year survival rate of the 19 patients with thrombocytosis was significantly worse than that of the patients without thrombocytosis (61 vs 96%, P < 0.0001). The recurrence rate was significantly higher in patients with thrombocytosis than in those with a platelet count <400,000/microL (7 vs 32%, P < 0.005). In a multivariate analysis, thrombocytosis continued to be a predictor of worse prognosis. In conclusion, we found thrombocytosis to be a prognostic factor for survival in patients with endometrial carcinoma.
我们回顾了135例连续的子宫内膜癌患者中血小板增多症（血小板计数≥400,000/μL）的患病率及其与预后的关系，并将血小板计数与其他预后因素进行了比较。135例患者中有19例（14%）存在血小板增多症。血小板增多症在晚期疾病（II-IV期）、不良分级（G2和G3）、子宫肌层深部浸润和淋巴血管间隙浸润中更为常见。总体5年生存率为92%。19例血小板增多症患者的5年生存率明显低于无血小板增多症的患者（61%对96%，P<0.0001）。血小板增多症患者的复发率明显高于血小板计数<400,000/μL的患者（7%对32%，P<0.005）。在多变量分析中，血小板增多症仍然是预后较差的一个预测因素。总之，我们发现血小板增多症是子宫内膜癌患者生存的一个预后因素。
